Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Seagen Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
This Biotech's Stock Has Been Under Pressure, Could Upcoming Clinical Trials Of Its Nanotechnology-Based COVID Drug Candidate Be The Start Of An Upward March?
A company that seems to have seen poor market sentiment lately is NanoViricides Inc. (NYSEAMERICAN: NNVC), a pharmaceutical company specializing in the development of nanomedicine drugs for treating... 
Via Benzinga
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the... 
Via Benzinga
Here's How Much You Would Have Made Owning Seagen Stock In The Last 5 Years
 
Via Benzinga
Consider This Undervalued Pharma Giant Before Its Blockbuster Deal Closes
Wall Street isn't showing one of pharma's most prominent players any love. 
Via The Motley Fool
Is Pfizer Stock a Buy, Sell or Hold? Here’s My Call.
Pfizer can't depend on Covid-19 vaccines as a revenue source in 2023, but PFE stock can still grow as the drugmaker broadens its pipeline. 
Via InvestorPlace
Here's How Much You Would Have Made Owning Seagen Stock In The Last 5 Years
 
Via Benzinga
Analyst Ratings for Seagen
 
Via Benzinga
Here's How Much You Would Have Made Owning Seagen Stock In The Last 5 Years
 
Via Benzinga
A Bullish Sign Appears On Seagen's Chart
 
Via Benzinga
FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer
 
Via Benzinga
Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run
Viking Therapeutics stock might in the midst of a historic run. 
Via The Motley Fool
It's Not Tesla, Meta Or Nvidia — The Best Performing Large-Cap Stock In 2023 Is A Crypto Play
The SPDR S&P 500 ETF Trust (NYSE: SPY) has seen a positive return in 2023. Several sectors are in the green so far this year, and many well-known stocks are among the biggest gainers. Here’s a look at... 
Via Benzinga
Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer
 
Via Benzinga
3 Low P/E Stocks That Are Bound to Rebound This Year
These are the low P/E stocks to buy at current levels for a sharp reversal rally in the coming quarters. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023
 
Via Benzinga
Why Pfizer Likely Isn't Done With M&A After the Seagen Deal
Pfizer's stock remains down despite its latest dealmaking, but it may only be a matter of time before it starts to rally. 
Via The Motley Fool
Pfizer Has Another Blockbuster on the Horizon, but That's Not All
The drugmaker continues to grab headlines for the right reasons. 
Via The Motley Fool
1 Top Healthcare Stock That Could Make You Richer in the Next Decade
The Pfizer of tomorrow will be larger and even more lucrative to hold than it is now. 
Via The Motley Fool
Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement
Livzon Pharmaceutical Group entered a $127.5 million agreement for China rights to a gastroesophageal reflux disease therapy from Onconic Therapeutics. Meanwhile, Gracell Biotech announced that it had... 
Via Talk Markets
Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review
A market rally is underway, but bank stocks kept tumbling. 
Via Investor's Business Daily
This Must-Buy Dividend Growth Stock Could Pay You for Life
It might not regularly beat the market, but it won't have any trouble padding your wallet. 
Via The Motley Fool
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for another dive into the biggest pre-market stock movers as we go over all the latest news for Thursday morning! 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2023
 
Via Benzinga
Drug Companies Raising Prices Greater Than Inflation? US Government Mulling Imposing Fines
Under Joe Biden's signature Inflation Reduction Act, drugmakers for twenty-seven drugs will be penalized for charging prices that rise faster than inflation for people with disabilities or the elderly... 
Via Benzinga
Meta Platforms To Rally Over 36%? Here Are 10 Other Analyst Forecasts For Wednesday
Credit Suisse cut the price target for Zscaler, Inc. (NASDAQ: ZS) from $275 to $165. Credit Suisse analyst Sami Badri maintained an Outperform rating. Zscaler shares fell 1.9% to $105.95 in pre-market... 
Via Benzinga
Does This Billion-Dollar Deal Solve Pfizer's Biggest Problem?
Pfizer's planned acquisition of Seagen could be a very important move. 
Via The Motley Fool
Key Inflation Meter Doesn't Show New Signs for Concern and Stocks Begin Shaking Off Instability
(Tuesday Market Open) The first of this week’s three critical data releases, February’s Consumer Price Index (CPI), was pretty much in line with expectations Tuesday, perhaps easing some concerns about... 
Via Benzinga
Is Pfizer Stock a Screaming Buy After Its $43 Billion Seagen Acquisition?
Pfizer's $43 billion Seagen acquisition is a long-term value-creation strategy. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023
 
Via Benzinga
These Analysts Boost Price Targets On Seagen Following Acquisition News
Pfizer Inc (NYSE: PFE) agreed to acquire Seagen Inc (NASDAQ: SGEN) for $229 in cash per Seagen share for a total enterprise value of $43 billion. Seagen shares jumped 14.5% to close at $197.65 on... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.